Search research articles
Contact Us
Filters
Showing results (1-10 of 525) with videos related to
Page
of 53
Sort By:
Journal of Cardiac Failure
|
August 25, 2009
Heart failure with a normal ejection fraction (HFNEF): embracing complexity
Mathew S Maurer
Journal of the American College of Cardiology
|
October 18, 2003
Age: a nonmodifiable risk factor?
Mathew S Maurer
Journal of the American Geriatrics Society
|
June 8, 2020
Norma: Participant 1,001 and the Value of Clinical Research
Mathew S Maurer
The New England Journal of Medicine
|
August 4, 2021
Gene Editing - A Cure for Transthyretin Amyloidosis?
Mathew S Maurer
The New England Journal of Medicine
|
December 11, 2002
Obesity and the risk of heart failure
Mathew S Maurer
The American Journal of Medicine
|
June 21, 2015
Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology
Mathew S Maurer
JACC. Cardiooncology
|
August 16, 2021
Call for New Therapies in Heart Failure: How Cardiology Can Learn From Oncology
Mathew S Maurer
Journal of Cardiac Failure
|
February 13, 2025
A Question in the Era of Multiple Effective Therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Is Transthyretin Biology a Driver of Disease Progression?
Mathew S Maurer
The American Journal of Cardiology
|
November 12, 2022
Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy
Mathew S Maurer
Current Treatment Options in Cardiovascular Medicine
|
June 5, 2012
Heart failure with a normal ejection fraction: treatments for a complex syndrome?
Samuel Bernard, Mathew S Maurer
Page
of 53
Search research articles
Search
Showing results (1-10 of 525) with videos related to
Sort By:
Page
of 53
Journal of Cardiac Failure
|
August 25, 2009
Heart failure with a normal ejection fraction (HFNEF): embracing complexity
Mathew S Maurer
Journal of the American College of Cardiology
|
October 18, 2003
Age: a nonmodifiable risk factor?
Mathew S Maurer
Journal of the American Geriatrics Society
|
June 8, 2020
Norma: Participant 1,001 and the Value of Clinical Research
Mathew S Maurer
The New England Journal of Medicine
|
August 4, 2021
Gene Editing - A Cure for Transthyretin Amyloidosis?
Mathew S Maurer
The New England Journal of Medicine
|
December 11, 2002
Obesity and the risk of heart failure
Mathew S Maurer
The American Journal of Medicine
|
June 21, 2015
Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology
Mathew S Maurer
JACC. Cardiooncology
|
August 16, 2021
Call for New Therapies in Heart Failure: How Cardiology Can Learn From Oncology
Mathew S Maurer
Journal of Cardiac Failure
|
February 13, 2025
A Question in the Era of Multiple Effective Therapies for Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Is Transthyretin Biology a Driver of Disease Progression?
Mathew S Maurer
The American Journal of Cardiology
|
November 12, 2022
Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy
Mathew S Maurer
Current Treatment Options in Cardiovascular Medicine
|
June 5, 2012
Heart failure with a normal ejection fraction: treatments for a complex syndrome?
Samuel Bernard, Mathew S Maurer
Page
of 53